EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictive value of gB2 antibodies for maternal–fetal transmission after primary cytomegalovirus infection treated with valacyclovir

K O Kagan iD, A L Bissinger, O Roth, J Sonek, M Hoopmann, Y Ville iD, M Enders

Ultrasound in Obstetrics & Gynecology · 2026-04 · 67 (4) · 455-460

DOI: 10.1002/uog.70206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ultrasound in Obstetrics & Gynecology, online erschienen am 30.03.2026. Verfasst von K O Kagan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, University of Tübingen, Tübingen, Germany. Hauptthemen laut MEDLINE: Valacyclovir, Cytomegalovirus Infections, Antiviral Agents, Infectious Disease Transmission, Vertical. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To estimate the residual risk of maternal–fetal transmission after primary cytomegalovirus (CMV) infection in the periconceptional period or the first trimester in women treated with valacyclovir, and to assess whether the presence of glycoprotein B2 (gB2)‐specific immunoglobulin (Ig)‐G antibodies on immunoblot analysis refines fetal risk prediction.

Methods

This was a retrospective single‐center study conducted at University Hospital Tübingen, Tübingen, Germany, between October 2023 and June 2025. Pregnant women with a primary CMV infection diagnosed < 14 weeks' gestation who received valacyclovir (8 g/day) were included in the study. The diagnosis of a recent primary CMV infection was based on maternal serology results, specifically positive anti‐CMV‐immunoglobulin (Ig)‐G and ‐IgM levels, and low or intermediate IgG avidity. Additionally, prior to initiation of valacyclovir treatment, the presence or absence of glycoprotein B (gB)2‐specific IgG antibodies was determined using a commercial line immunoblot. The primary outcome was maternal–fetal transmission of CMV detected at the time of second‐trimester amniocentesis.

Results

Eighty‐five women met the inclusion criteria, including 47 with periconceptional and 38 with first‐trimester maternal CMV infection. Median maternal and gestational age at the time of diagnosis of primary maternal CMV infection were 33.1 (interquartile range (IQR), 29.9–34.9) years and 7.4 (IQR, 6.4–8.9) weeks, respectively. Amniocentesis was performed at a median gestational age of 20.6 (IQR, 20.1–21.0) weeks. Overall, maternal–fetal transmission was detected in 7/85 (8.2%) cases at the time of amniocentesis. All CMV transmissions occurred in women without gB2‐specific IgG antibodies (7/55 (12.7%)), while no transmissions occurred in those with gB2‐specific IgG antibodies (0/30 (0%)) ( P = 0.048).

Conclusions

In women with a primary CMV infection treated with valacyclovir, the presence of gB2‐specific IgG antibodies on immunoblot analysis identifies a subgroup with a low residual risk of maternal–fetal transmission. Incorporating gB2‐specific IgG antibodies status into risk stratification may improve patient counseling and clinical decision‐making. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ValacyclovirCytomegalovirus InfectionsAntiviral AgentsInfectious Disease Transmission, VerticalPregnancy Complications, InfectiousViral Envelope ProteinsAntibodies, ViralHumansFemalePregnancyRetrospective StudiesAdultImmunoglobulin GPredictive Value of TestsCytomegalovirus

Stichwörter der Autor:innen

CMVgb2 antibodiespregnancytransmissionvalacyclovir

Substanzen

ValacyclovirAntiviral Agentsglycoprotein B, SimplexvirusViral Envelope ProteinsImmunoglobulin GAntibodies, Viral

Autor:innen und Institutionen

  • Department of Obstetrics and Gynaecology, University of Tübingen, Tübingen, Germany.
  • Institute of Medical Virology and Epidemiology of Viral Diseases, University of Tübingen, Tübingen, Germany.
  • Fetal Medicine Foundation USA, Dayton, OH, USA.
  • Division of Maternal Fetal Medicine, Wright State University, Dayton, OH, USA.
  • EA Fetus, Paris Descartes University, University of Paris, Paris, France.
  • Department of Obstetrics, Fetal Medicine and Surgery, Necker-Enfants Malades Hospital, AP-HP, Paris, France.

ORCID-Profile: K O Kagan, Y Ville

Zitieren

APA

Kagan, K. O., Bissinger, A. L., Roth, O., Sonek, J., Hoopmann, M., Ville, Y., & Enders, M. (2026). Predictive value of gB2 antibodies for maternal–fetal transmission after primary cytomegalovirus infection treated with valacyclovir. Ultrasound in Obstetrics & Gynecology, 67(4), 455-460. https://doi.org/10.1002/uog.70206

Vancouver

Kagan KO, Bissinger AL, Roth O, Sonek J, Hoopmann M, Ville Y, et al. Predictive value of gB2 antibodies for maternal–fetal transmission after primary cytomegalovirus infection treated with valacyclovir. Ultrasound in Obstetrics & Gynecology. 2026;67(4):455-460. doi:10.1002/uog.70206

BibTeX
@article{Kagan2026,
  author = {Kagan, K O and Bissinger, A L and Roth, O and Sonek, J and Hoopmann, M and Ville, Y and Enders, M},
  title = {Predictive value of gB2 antibodies for maternal–fetal transmission after primary cytomegalovirus infection treated with valacyclovir},
  journal = {Ultrasound in Obstetrics & Gynecology},
  year = {2026},
  volume = {67},
  number = {4},
  pages = {455--460},
  doi = {10.1002/uog.70206}
}
Kostenlos starten →